Chang Gung Memorial Hospital, Chang Gung University College of Medicine, No. 5, Fu Shin Street, Kweishan, Taoyuan, Taiwan, R.O.C.
Anticancer Res. 2010 Jan;30(1):253-9.
BACKGROUND/AIM: Glioblastoma and astrocytoma are the most common brain tumors affecting adults 45-60 years of age. The poor prognosis for glioblastoma patients results from recurrence after treatment. There is therefore an urgent need to develop diagnostic and prognostic markers as well as new therapies.
Microarray analyses of clinical specimens from glioblastoma patients were used to identify potential tumor markers. Expression of candidate genes was analyzed by real-time reverse transcription-polymerase chain reaction and by immunoblotting and immunohistochemistry.
Five potential markers (CD44 antigen (CD44), growth arrest and DNA-damage-inducible, alpha (GADD45A), fibronectin 1 (FN1), CD63 antigen (CD63) and secreted phosphoprotein 1 (SPP1)) showed expression patterns that correlated significantly with malignant glioma. In particular, expression of the CD44 antigen was elevated in more severe tumor types, and higher in tumor cores than in peripheral regions. However, lower levels of CD44 expression surprisingly correlated with lower survival.
The CD44 antigen is a promising candidate for further development as a prognostic and therapeutic tool.
背景/目的：胶质母细胞瘤和星形细胞瘤是最常见的影响 45-60 岁成年人的脑肿瘤。胶质母细胞瘤患者预后不良的原因是治疗后复发。因此，迫切需要开发诊断和预后标志物以及新的治疗方法。
使用来自胶质母细胞瘤患者的临床标本的微阵列分析来鉴定潜在的肿瘤标志物。通过实时逆转录聚合酶链反应以及免疫印迹和免疫组织化学分析候选基因的表达。
五种潜在的标志物（CD44 抗原（CD44）、生长停滞和 DNA 损伤诱导，α（GADD45A）、纤连蛋白 1（FN1）、CD63 抗原（CD63）和分泌磷蛋白 1（SPP1））表现出与恶性神经胶质瘤显著相关的表达模式。特别是，CD44 抗原的表达在更严重的肿瘤类型中升高，在肿瘤核心区域比在周边区域升高。然而，令人惊讶的是，较低的 CD44 表达水平与较低的存活率相关。
CD44 抗原是进一步开发作为预后和治疗工具的有前途的候选物。
